Investigational drug · Phase 3
elsunersen
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Epileptic Encephalopathy, SCN2A Encephalopathy.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "elsunersen"
First trial start
2025
Aug 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "elsunersen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epileptic Encephalopathy
- SCN2A Encephalopathy
Approved drugs for the same conditions: Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "elsunersen" as an intervention, largest first.
- A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyPivotal-lookingRecruiting
Praxis Precision MedicinesIndustry
NCT07019922 · 40 participants (planned) · Start Aug 13, 2025 · Primary completion Dec 2026
Drug: 1mg elsunersen; 0.5mg elsunersen · For: Epileptic Encephalopathy; SCN2A Encephalopathy
Sites: San Diego, California; Aurora, Colorado; Chicago, Illinois · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Antisense Oligonucleotidesin Genetic Epilepsies and Developmental and Epileptic Encephalopathies: Molecular Mechanisms, Translational Evidence and Disease-Modifying Potential.
Leo A, Roberti R, Vono PF, et al. · Biology (Basel) 2026
- Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.
Bialer M, Johannessen Landmark C, Koepp MJ, et al. · Epilepsia 2026
- Antiseizure Medications in Development: Novel Mechanisms, Precision Therapy, and the Move Towards Disease Modification.
Martins WA · Curr Issues Mol Biol 2026
- From Symptomatic Therapies to Disease-Modifying Approaches for Neuronal Sodium Channel Disorders.
Dinoi G, Canfora I, D'Agnano D, et al. · Int J Mol Sci 2025
- Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy.
Wagner M, Berecki G, Fazeli W, et al. · Nat Med 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.